Rubric Capital Management LP Purchases 100,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Rubric Capital Management LP boosted its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 6.3% during the second quarter, Holdings Channel reports. The institutional investor owned 1,700,000 shares of the biotechnology company’s stock after buying an additional 100,000 shares during the period. Heron Therapeutics accounts for approximately 4.9% of Rubric Capital Management LP’s investment portfolio, making the stock its largest position. Rubric Capital Management LP’s holdings in Heron Therapeutics were worth $23,545,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Tang Capital Management LLC boosted its stake in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock valued at $129,824,000 after buying an additional 2,457,716 shares in the last quarter. FMR LLC boosted its stake in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Janus Capital Management LLC boosted its stake in Heron Therapeutics by 20.2% in the first quarter. Janus Capital Management LLC now owns 5,501,755 shares of the biotechnology company’s stock valued at $82,524,000 after buying an additional 925,948 shares in the last quarter. Broadfin Capital LLC boosted its stake in Heron Therapeutics by 26.9% in the first quarter. Broadfin Capital LLC now owns 4,947,403 shares of the biotechnology company’s stock valued at $74,211,000 after buying an additional 1,047,816 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Heron Therapeutics by 40.2% in the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after buying an additional 537,563 shares in the last quarter.

Heron Therapeutics, Inc. (NASDAQ:HRTX) opened at 16.00 on Friday. The stock has a 50 day moving average of $15.38 and a 200-day moving average of $14.57. Heron Therapeutics, Inc. has a 12-month low of $12.21 and a 12-month high of $22.01.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million. On average, analysts anticipate that Heron Therapeutics, Inc. will post ($3.74) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This report was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/08/13/rubric-capital-management-lp-purchases-100000-shares-of-heron-therapeutics-inc-nasdaqhrtx.html.

HRTX has been the subject of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, July 12th. Cowen and Company reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a research report on Friday, May 26th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Thursday. Finally, ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. One analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $31.00.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply